PRO Stock Overview
Societe de Promotion Pharmaceutique du Maghreb S.A. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Societe de Promotion Pharmaceutique du Maghreb S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.م910.00 |
| 52 Week High | د.م1,150.00 |
| 52 Week Low | د.م873.00 |
| Beta | -0.086 |
| 1 Month Change | 3.41% |
| 3 Month Change | -17.20% |
| 1 Year Change | -9.00% |
| 3 Year Change | -20.18% |
| 5 Year Change | 6.31% |
| Change since IPO | -6.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| PRO | MA Pharmaceuticals | MA Market | |
|---|---|---|---|
| 7D | -4.2% | -1.5% | -0.8% |
| 1Y | -9.0% | -9.7% | 17.9% |
Return vs Industry: PRO matched the MA Pharmaceuticals industry which returned -9.3% over the past year.
Return vs Market: PRO underperformed the MA Market which returned 18% over the past year.
Price Volatility
| PRO volatility | |
|---|---|
| PRO Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in MA Market | 7.5% |
| 10% least volatile stocks in MA Market | 2.2% |
Stable Share Price: PRO's share price has been volatile over the past 3 months compared to the MA market.
Volatility Over Time: Insufficient data to determine PRO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | n/a | Salameh Al Araideh | www.promopharm.co.ma |
Societe de Promotion Pharmaceutique du Maghreb S.A. produces, commercializes, imports, and exports medicines, derma-pharmaceuticals, and cosmetic products in Africa. It subcontracts medicines for national and international laboratories. The company was founded in 1947 and is headquartered in Had-Soualem, Morocco.
Societe de Promotion Pharmaceutique du Maghreb S.A. Fundamentals Summary
| PRO fundamental statistics | |
|---|---|
| Market cap | د.م910.00m |
| Earnings (TTM) | د.م56.90m |
| Revenue (TTM) | د.م805.52m |
16.0x
P/E Ratio1.1x
P/S RatioIs PRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRO income statement (TTM) | |
|---|---|
| Revenue | د.م805.52m |
| Cost of Revenue | د.م446.27m |
| Gross Profit | د.م359.24m |
| Other Expenses | د.م302.34m |
| Earnings | د.م56.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 56.90 |
| Gross Margin | 44.60% |
| Net Profit Margin | 7.06% |
| Debt/Equity Ratio | 27.1% |
How did PRO perform over the long term?
See historical performance and comparisonDividends
4.4%
Current Dividend Yield65%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 04:58 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Societe de Promotion Pharmaceutique du Maghreb S.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yasmina El Omari | CFG Marches |